Bio-Gene Technology Limited (ASX:BGT or ‘Bio-Gene’ or ‘the Company’), an Australian company developing the next generation of novel insecticides derived fro... Flavocide: taking a new insecticide from leaf to lab Date:Dec. 4, 2023 ...
全球杀虫剂抗药性和毒性研究开发公司Bio-Gene Technology Limited(ASX:BGT)宣布了一项全球性重大突破,其试验结果证实FlavocideTM可以控制携带疟疾的冈比亚按蚊蚊种,该蚊种对常用杀虫剂的抵抗力正日益增强。 公司首席执行官理查德·贾格尔(Richard Jagger)在评论时称,“实验室试验结果表明,FlavocideTM对具有抗药性的冈比亚...
Bio-Gene Technology Ltd的公允价值上行边际 (InvestingPro)排名为第4.7%名,处于板块内49.8%的水平。下表提供了更多数据的摘要: 板块材料的公允价值上行边际 (InvestingPro) 经济风险区类别 发达 全部成分股 2,987 包括的成分股 2,867 分钟 -52.7% 最大值 62.3% 中位数 4.8% 平均值 2.9% 标准差 27.3% 用本...
Q1. Could you briefly introduce Bio-Gene Technology? Bio-Gene Technology Limitedis developing new, novel insecticides based on natural molecules. These molecules are quite unique in that they have a novel insecticidal “Model of Action”, which means they work very differently to all other chemistr...
Bio-Gene Technology Limited Australia Follow STK Israel FollowBy Louis Allen Agtech development company Bio-Gene Technology (BGT) has agreed to enter a global collaboration with STK Bio-Ag Technologies. STK is an Israel-based Agtech company most known for its botanical-based solutions for crop ...
5158877 Gene synthesis: Richad Edwards, Sally E Adams, Thame, United Kingdom assigned to British Bio-Technology Limiteddoi:10.1016/0734-9750(93)90433-NSDOSBiotechnology Advances
Gene therapy for many diseases is rapidly becoming a reality, as demonstrated by the recent approval of various nucleic acid-based therapeutics. Non-viral systems such as lipid-based carriers, lipid nanoparticles (LNPs), for delivering different payloads including small interfering RNA, plasmid DNA,...
This technology has led to a rapid growth in scRNA-seq data, necessitating the analysis of these datasets to extract various types of information. Single-cell data analysis is a multi-step process encompassing preprocessing and downstream analysis at both the cell and gene levels, with a crucial...
Professor Wei Wang of Tongji Hospital, Tongji Medical School of Huazhong University of Science and Technology, the principal investigator of this clinical study,said, "The existing treatment options for autoimmune diseases are limited. Autoimmune diseases are difficult to cure, and recurrent attacks brin...
Equecabtagene Autoleucel employs second-generation CAR technology to precisely identify and eliminate cells expressing BCMA. By clearing the activated B cells and plasma cells from the body of the SLE patients, it reduces the pathogenic cells and autoantibodies, thereby suppressing autoimmune inflammat...